AGTC Receives $2 Million Milestone from Genzyme After Successful Transfer of Novel Production Technology June 21, 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that it has received a $2 million milestone payment
AGTC and JDRF announce partnership to develop gene therapy for diabetic eye disease May 16, 2006 – The Juvenile Diabetes Research Foundation has joined in a partnership with AGTC (Applied Genetic Technologies Corp.) and Genzyme Corporation to develop a gene therapy treatment to potentially prevent
AGTC Announces Initiation of New Phase 1 Clinical Trial February 23, 2006 - Applied Genetic Technologies Corporation (AGTC), a private clinical-stage biotechnology company, announced today the initiation of a Phase 1 clinical study to test the safety of AGTC-0106, its investigational gene therapy
Genzyme, AGTC Announce Gene Therapy Collaboration December 6, 2004 - Genzyme Corporation and Applied Genetic Technologies (AGTC), a private development-stage biotechnology company, announced today that they have entered into a research collaboration to jointly develop novel therapeutics involving
AGTC Raises $15,250,000 in Series A-1 Round December 1, 2003 - Applied Genetic Technologies Corporation, AGTC, a drug research company developing novel human therapeutics, announces that the Company has closed on a $15,250,000 Series A-1 Round led by InterWest Partners of Menlo Park, CA.
